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Introduction
One of the most severe mental disorders leading to 
a disturbance in the percipience of reality is named 
schizophrenia1. Schizophrenia has defined by one or all 
of these following symptoms: delusions, hallucinations, 
disorganized thinking (speech), and negative symptoms 
that the severity of them impairs normal thinking and 
behavior, and in general, disrupts the ability to perform 
daily activities.2 Having Schizophrenia requires the 
patient to receive medication for a lifetime,3 which 
imposes a substantial economic burden on the patient 
and their relatives.4 Starting treatment in the early 
stages of the disease is more effective in controlling the 
progression and preventing more severe symptoms.1 The 
onset of schizophrenia in the 20s-30s is common, and 
the risk for more aged people is remarkably rare.5 Global 
statistics investigations revealed that approximately 25 
million people are affected.6 Based on this information 
and estimation of the economic burden for schizophrenia, 
the vacancy of more economical and practical therapeutic 
approaches has felt. To achieving this purpose, precise 
cognition of symptoms and their causes has required.  
Symptoms 
Behavioral, intellectual, and emotional disorders indicate 
the widespread impact of schizophrenia on various aspects 
of mental health. Although the signs and symptoms of 
schizophrenia are very varied, delusions, hallucinations, 
or disorganized speech included in common symptoms.7 
Based on the general symptom classification, there is 
three dominant class of schizophrenia symptoms which 
are including (1) positive (2) negative and cognitive, 
which have described in detail below.8
Delusions
It is a definite symptom that means false thoughts that 
are not objective and real. For instance: believing that you 
have been harassed or harmed. You find yourself under 
the command of something unrealistic. You are incredibly 
talented and famous, someone loves you infinitely, 
announcing a close catastrophe.9 Almost all people with 
schizophrenia access delusions. Many recent studies 
reported an evidenced correlation between delusion and 
bias against disconfirmatory evidence.10
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Hallucinations
It is another positive symptom class and comes when 
a person’s perception feels beyond reality, although a 
person with schizophrenia experiences these feelings 
objectively. Hallucinations may occur for all five senses; 
hearing imaginary noises is more common than others.11
Disorganized Thinking (Speech)
Disorganized thinking has inferred from disorganized 
speech. It will be impossible to communicate effectively 
with a person with schizophrenia due to unrelated 
answers to questions, whether partial or general. On rare 
occasions, the speech has included expressing sentences 
that contain meaningless and irrelevant words known as 
word salad; therefore, it will be incomprehensible to the 
listener.12
Negative Symptoms 
This means that daily activities have almost disrupted. 
For example, the person may neglect personal hygiene or 
appear to lack emotion (does not make eye contact, does 
not change facial expressions or speaks in a monotone).13,14 
Also, the person may lose interest in everyday activities, 
socially withdraw, or cannot experience pleasure.15 
Periodic improvement and worsening of symptoms have 
created a wide range of severity and type of symptoms.16 
The onset of symptoms of schizophrenia in men occurs in 
the middle of the third decade of life, while in women, the 
symptoms occur in the late twenties.17
Schizophrenia Etiology
Schizophrenia is a complex disease of unknown etiology. 
The occurrence of schizophrenia as a multifactorial disease 
is related to genetics, environment, and pathophysiological 
factors, it shows a combination of behavioral and mental 
problems ultimately.18 Schizophrenia is a testament 
to the intense interaction between genetics19 and 
the environment.18 The neurochemical hypothesis,18 
genetic susceptibility,20 immunological alteration,21 and 
environmental factors such as multiple infections are the 
primary etiological response of schizophrenia.22
Dopamine Hypothesis 
The dopamine hypothesis is the earliest etiology of 
schizophrenia and has been an important topic of 
schizophrenia investigations for decades.23 It has shown 
that the amount of dopamine in a stratum is more than 
average in schizophrenia patients compared with healthy 
people.24 Excess dopamine intensifies of psychotic 
symptoms in patients is correlated with increases in 
released dopamine levels. Excess secretion of dopamine 
is observant significantly throughout exacerbation in 
comparison to remission periods.25 Additionally, using 
a higher-resolution scanner and more sophisticated 
region-of-interest analysis methods to identify the striatal 
substructures demonstrates that excess striatal dopamine 
was most prominent in the rostral caudate.26 Significant 
enhancement in dopamine secretion throughout the 
cortex is measurable. Dopamine release in the dorsolateral 
prefrontal cortex (DLPFC) was significantly positively 
associated with working memory-related BOLD 
activation, suggesting a relationship between the blunted 
release and deficits of frontal cortical function.27
The Role of GABA in Schizophrenia
Some evidence demonstrates the altering of GABAergic 
neurotransmission in schizophrenia and counted as the 
main convincing reason for cognitive defects in patients. 
Postmortem data suggest that GAD67 mRNA translation 
in the DLPFC has initially decreased through layers 1 to 5, 
resulting in decreased GAD67 protein levels.28 It can cause 
a reduction in the number of neurons in schizophrenia. 
Based on these studies, it has claimed that the disturbance 
in GAD67 gene expression occurs exclusively in a specific 
subset of GABAergic neurons.29 Additionally, Postsynaptic 
GABA Receptors can play a crucial role in schizophrenia. 
Owing to recent advances in medical technology, more 
accurate investigations of deficits of GABA-A receptor 
subunits are possible.30
Neuroinflammatory Mechanisms in Schizophrenia
For many years, the association of dopamine levels with 
schizophrenia has been a significant target of researches. 
However, these days there is an innovative trend based 
on new evidence that has concentrated on a particular 
emphasis on the accurate performance of the immune 
system.31 Based on it, the role of neuroinflammation and 
defect in immune system function is a potent factor in 
the development of schizophrenia and the symptoms of 
psychosis in patients.32 Epidemiological data and historical 
observations have drawn the attention of researchers to 
inflammatory processes for decades. Recently extensive 
research on exposure to infection, stress-induced 
inflammatory response, glial cell signaling, structural 
and functional brain changes, and therapeutic trials have 
confirmed that inflammation can be an effective factor 
in the appearance and development of schizophrenia.33 
Accordingly, severe infections and autoimmune diseases 
can increase the risk of schizophrenia and related disorders. 
Due to aberrations in the immune system and high level 
of pro-inflammatory cytokines during pregnancy, the 
mother will be more vulnerable to infections.34 In seasons 
when the influenza epidemic is more prevalent, the 
exposure to infection naturally increases, resulting in an 
increased risk of congenital disabilities in children prone 
to schizophrenia.35 Also, respiratory and reproductive 
tract infections have considered as an increasing factor 
of the onset risk of offspring to schizophrenia.36 Other 
pathogens linked to schizophrenia include maternal 
infection with Toxoplasma gondii, rubella, measles, polio, 
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and herpes simplex type 2.37 Besides studies that have 
corroborated the role of environmental factors in the 
occurrence of prenatal infections, attention has focused 
on the whole genomic studies in new approaches since 
immune-related genes have discovered in schizophrenia 
patients.38 According to this fresh information, recent 
studies have attempted to identify polymorphisms and 
immune system alteration to approve the risk of infections 
that can be rooted in a person’s genetics.39 In addition to 
environmental factors that cause infection, researches 
have shown that genetic polymorphisms can increase a 
person’s susceptibility to schizophrenia.40 These genetic 
variations can include the immune system divergent genes 
involved or alterations in response to infectious agents.41 
Extensive study groups have tracked the polymorphisms 
vulnerable to schizophrenia on different gene loci located 
on chromosome 6p22. HLA complex genes, moderator 
the inflammatory response, were the major correlated 
genes.42
Effective Genes in Schizophrenia
Schizophrenia is a highly heritable disorder with 
monozygotic concordance rates of approximately 50% 
and dizygotic concordance rates of approximately 10%. 
Genomewide association studies have identified several 
common variants that are associated with schizophrenia.43 
Some of the pathways implicated in these studies have 
involved neural differentiation, synaptic transmission, 
and circuit development, lending weight to the hypothesis 
that schizophrenia is a developmental disorder. There 
are almost 608 genes that can cause schizophrenia.44 
Principally genes schizophrenia expression should be 
traceable in organs such as the cerebellum, cerebral 
cortex, medulla oblongata, thalamus, and hypothalamus.45 
Psychiatric behavioral disorders incorporating 
schizophrenia genes included ADHD, bipolar disorder, 
autism spectrum disorder, alcohol dependence, cancer, 
Alzheimer’s and Parkinson’s disease, sleep disturbances, 
and inflammation.46 By taking advantage of recent studies 
and approaches, by exploring biological pathways and 
analyzing genes related to schizophrenia, numerous 
related genes have identified which listed in Table 1.45,47
Biological mechanisms involving synaptic 
transmission, regulation of membrane potential, and 
transmembrane ion transport have identified as before 
cellular applications related to schizophrenia genes.48 
Additionally, some genetically neurological disorders 
that their induced pluripotent stem cells (iPSCs) associate 
with schizophrenia patients. For instance, it has shown in 
a study that iPSCs with del 22q11.2 (DiGeorge syndrome) 
identified in schizophrenia patients.49,50 Furthermore, the 
variety in copy number of 15q11.2 links to schizophrenia, 
and it causes a reduction in adherence junctions and 
retains proper apical polarity.51,52
The Treatments of Schizophrenia
There have been various ways for curing schizophrenia 
of past decades. Contrary to different functional 
mechanisms of three classes of antipsychotic medications 
(conventional typical, atypical, and dopamine partial 
agonist) operate base on the dopamine system. 
Additionally, the antioxidant drugs are beneficial during 
treatment, and cannabidiol has neuronal and molecular 
effects on the mesolimbic dopamine system.53 The use 
of these drugs is not very satisfactory for reasons such 
as multiple side effects, lack of effect on the negative 
or cognitive symptom, and not valid for all patients.54 
There are currently no FDA-approved medications 
available to reduce the negative and cognitive symptoms 
of schizophrenia, which are the leading causes of patient 
disruption life.55   Negative symptoms, such as blunted 
affect, and social avoidance, and cognitive symptoms, 
like deficits in attention and executive function, reduce 
capable of life, extremely.56 Even among schizophrenia 
patients who respond to antipsychotic medications, 
disability is significant, and functional consequences 
are disappointing. Therefore, the need for immediate 
treatment for negative and cognitive symptoms of 
schizophrenia is greatly felt.57 The complexity and 
multifactorial nature is a major obstacle to an accurate 
knowledge of schizophrenia, and as a result, it has 
become almost impossible to find a completely effective 
treatment for this disorder.58 Human-induced pluripotent 
stem cells (hiPSCs) supply a high-potential domain for 
a more accurate study of neurological disorders like 
schizophrenia. HiPSC provides an adequate opportunity 
that permits researchers to model and studies the exact 
mechanisms of the schizophrenia progression.59
The Induced Pluripotent Stem Cells 
In a groundbreaking discovery, Yamanaka showed that 
ectopic overexpression of the four transcription factors 
c-Myc, Klf4, Oct4, and Sox2 could reprogram fibroblasts 
into iPSCs.60 The human iPSCs generated in this manner 
share many characteristics with human blastocyst-derived 
embryonic stem cells (hESCs), including indefinite self-
renewal, clonogenicity, and pluripotency (the ability to 
differentiate into all adult cell types in the body).61 Hence, 
this reprogramming process enabled the generation of 
Table 1. Gene Families Involved in Schizophrenia
Gene Categories Genes Name
Glutaminergic receptors GRIA1, GRIN2, GRIK4, GRM5
Serotonergic receptors HTR2A, HTR2C
GABAergic receptors GABRA1, GABRB2
Dopaminergic receptors DRD1, DRD2
Calcium-related channels CACNA1H, CACNA1B
Solute transporters SLC1A1, SLC6A2
Neurodevelopmental genes ADCY1, MEF2C, NOTCH2, SHANK3
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hESC-equivalent pluripotent stem cells in the laboratory 
from readily available adult somatic cells, without any 
need for a human blastocyst.62 Human iPSCs can be 
differentiated into neurons using a variety of methods. 
Initial studies of schizophrenia using iPSCs have yielded 
some promising results.63 The first such study showed 
that neurons from schizophrenia patients had regular 
functional properties (as measured with electrophysiology 
and Ca2+ imaging), but displayed reduced connectivity, 
neurites, and synaptic protein levels.64 Schizophrenia 
neurons also had altered expression of genes involved 
in the Wnt, cAMP, and glutamate-signaling pathways.65 
A later study of these iPSCs showed that schizophrenia 
neural progenitor cells (NPCs) had an abnormal 
expression of genes and proteins related to cytoskeletal 
remodeling and oxidative stress pathways.66
Appropriate Cells in the Brain to Modeling the iPSC-
Derived Cells
There is no enough evidence to identify the relevant 
type of iPSCs-derived cells that can appear related 
symptoms to the disease. Although postmortem brains 
from patients demonstrate a decline in the volume of the 
cortex.67 Furthermore, it has shown that the volume of the 
hippocampus has reduced in patient’s brains. Especially 
in the dentate gyrus and cornu ammonis 3 hippocampal 
fields.68 Also, schizophrenia patients, the pyramidal 
neurons in the cortex, the spine density, and synapse 
numbers are decreased.69 As a result, the cell models from 
the cortex and hippocampus of schizophrenia patients 
can be appropriate to show the schizophrenia disease 
features and identify the new treatment approaches. The 
cortical neurons and hippocampal dentate gyrus neurons 
can use as differentiated cells from human iPSCs. The 
rate of homogeneity is noticeable in cultures.70 The 
heterogeneous neuronal cultures are beneficial since they 
are more similar to their original niches in the brain.
iPSC-Derived Cells Approach
To achieve advanced and effective treatment for 
schizophrenia by using stem cell-derived neurons; 
generally, two approaches are studied.
Reprogramming and Inducing Cells Using Viruses
For the first time, Chiang et al. claimed that hiPSCs 
have derived from schizophrenia patients; indeed, there 
was no information about differentiation.71 Brennand et 
al presented a new founded based on a defect of SCZD 
hiPSCs in neuronal connectivity. Additionally, they 
reported a significant reduction of post syntactical gene 
expression.59 In the first step, the iPSCs should reprogram. 
So the primary human fibroblasts are reprogrammed 
using inducible lentiviruses.72 There are two fundamental 
limitations to using viruses to reprogramming cells. First 
of all, the lack of complete suppression of viral genes, and 
the second is the risk of viral mutagenic gene insertion.59 
So, recently a doxycycline-inducible lentiviral system 
applied to silence viral genes completely.
While using adenovirus, plasmid vectors, however, with 
low efficiency, and synthetic modified mRNA approaches 
are developing for reprogramming.73 In the first step, 
and inducible lentiviruses are engaged to reprogram the 
primary human fibroblast. Schizophrenia hiPSCs have no 
evident deficiency in differentiation NPCs and neurons.74 
To ensure the differentiation of hiPSC to the NPCs and 
neurons, the trans-neuronal spread of rabies is a reliable 
tool for evaluating synaptic communication. The synaptic 
contacts make rabies transmission and are associated 
with synaptic input potential.75 Though there are 
ambiguous sides of rabies trans-neuronal tracing, NCAM 
as a presynaptic protein indicates reduced expression in 
schizophrenia hiPSC neurons.59 Trans-neural detection 
is the result of reduced neural connections; it does 
not necessarily lead to reduced synaptic function, in 
schizophrenia hiPSC neurons. In postmortem human 
studies and animal models repeating of some cellular 
and molecular phenotypes in hiPSC neurons from 
heterogeneous patients with similar deficits perceived. 
The decreased in neuronal connectivity in schizophrenia 
hiPSC neurons was observed.76 Expression studies of 
hiPSC neurons provide this possibility of intuition of 
antipsychotic treatment on live, genetically identical 
neurons with an effective response to treatment and 
pretermitting of confounding variables of postmortem 
analysis such as treatment history, drug or alcohol abuse, 
and cause of death.77 In the schizophrenia hiPSC neurons, 
of the 596 unique genes differentially expresses and the 
hypotheses based on pharmacological and genomewide 
association (GWAS) studies of schizophrenia has 
confirmed by gene expression profiles of schizophrenia 
hiPSC neurons and additionally, it identifies some novel 
pathways including NOTCH signaling, SLIT/ROBO axon 
guidance, EFNA mediated axon growth, cell adhesion, 
and transcriptional silencing.59 Multiple genes involved in 
increasing schizophrenia hiPSC neurons efficiency depend 
on schizophrenic pathways and have not recognized as 
specific genes involved in this disease, such as PDE family 
genes, ADCY8, and PDE4B.78  The use of human iPSCs 
to model individual patient’s cells has reinvigorated the 
hope that a new wave of targeted treatment opportunities 
will emerge soon. The five antipsychotic drugs have tested 
to modify neuronal connectivity in vitro. In the last 21 
days of neuronal differentiation, clozapine, loxapine, 
olanzapine, risperidone, and thioridazine have distributed. 
The loxapine in all patients is effective in enhancing the 
connection between neurons77 and realizing the best 
possible concentration, and the best time to administer 
drugs upgrades the antipsychotic medication efficiency.  
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Interneuron Transplants, Derived From Embryonic Stem 
Cells 
It has demonstrated that within developmental processes, 
the parvalbumin (PV) somatostatin (SST)-positive 
interneurons are brunched from the medial ganglionic 
eminence. The fetal medial ganglionic eminence tissue 
has used to restitute the function of interneurons in the 
methyl azoxy methanol (MAM) developmental model 
of schizophrenia.79 The interneuron transplants into 
the ventral hippocampus decrease the hyperactivity of 
hippocampal and also dopamine operation, and the 
amphetamine-induced locomotor activity will be at 
a  regular rate that is a model for positive symptoms of 
schizophrenia.80  By this method, the positive symptoms 
may be cured in the MAM model of schizophrenia and 
can be a functional approach to improving the negative 
and cognitive symptoms of patients whose treatment was 
not successful with antipsychotic medications.59
The observations show that the SST- and PV-enriched 
transplants can modify the behavioral disease differently. 
The transplants of SST and PV both can change the 
ventral hippocampus hyperactivity.
Unique anatomical, biochemical, and physiological 
characteristics of SST and PV make this variety of effects. 
For instance, the firing pattern can specialize in the PV- 
and SST-positive interneurons. As shown, the dopamine 
hypothesis claims that increased dopamine levels in 
the mesolimbic stimuli the positive symptoms, but by 
this method, both SST- and PV-positive interneuron 
transplants into the ventral hippocampus decline the 
dopamine population activity in MAM-treated animal 
models.78
One of the cognitive flexibilities is reversal learning, 
which shows a defect in schizophrenia, and reversal-
learning has associated with orbitofrontal activity and 
subcortical dopamine function. Also, community 
relations and extra-dimensional set-shifting, which linked 
with a part of the brain that receives direct projections 
from the ventral hippocampus and in schizophrenia 
patients are not regulated well, can be improved with only 
PV-positive transplants and can improve the disorders.81 
Generally, this strategy could be useful for the treatment 
of schizophrenia. However, the timing of the transplant 
should consider. The cells should be transplanted 
between postnatal day (PND) 40–45 and circulating 
androgen dosage. For using the MAM rodent model, the 
cell transplantation must perform as early as PND 40.76 
Another practical factor that should consider is the stage 
of schizophrenia. So the transplantation will be most 
effective if done in the earliest stage of the disease. 
Conclusion
Brain-imaging studies were the first approach in 
schizophrenia investigations. Although structural 
differences in healthy and patient groups have observed, 
brain studies were unable to determine the damaged parts 
of the nervous system accurately82 accurately. 
On the other hand, it identified the effective pattern of 
dopamine and glutamate in schizophrenia and applied the 
pharmacological treatment to improve severe symptoms. 
GWAS studies, with the onset of the genetic age, is 
beginning. These studies presented documented reports 
based on susceptibility to infection of polymorphisms.83 
Nevertheless, recent advances in cell therapy have given 
researchers an unprecedented and immense circumstance 
for recognizing and treating schizophrenia. While 
pharmacological treatment exclusively attempts to attack 
schizophrenia symptoms, cell therapy seeks to improve 
other neurological diseases, including Parkinson’s and 
stroke. The capacity of cell transplants in schizophrenia is 
not known well yet. Therefore there are lots of features of 
this that should achieve.
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